Melanoma Clinical Trial

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

Summary

Phase IV, open-label, randomized, two-arm, multi-center study in patients with metastatic melanoma who are treatment naïve or have previously received a single non-immunologic therapy.

Treatment Arm 1: Patients will receive two courses (four cycles) of High Dose Interleukin-2 (HD IL-2) followed by one course (four doses) of ipilimumab.

Treatment Arm 2: Patients will receive one course (four doses) of ipilimumab followed by two courses (four cycles) of HD IL-2.

View Full Description

Full Description

All patients will receive IL-2 at 600,000 international units per kilogram (kg) by intravenous bolus (IVB) every 8 hours for up to 14 planned doses with an additional cycle 14 days after the first.

Ipilimumab 3mg/kg IV infusion Q3 weeks up to 4 doses4 doses A 3-6 week interval been the administration of the two drugs to allow for resolution of treatment-related toxicities.

If corticosteroids were required during Ipilimumab administration, a 2-week period from discontinuation of steroid treatment to start of HD IL-2.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Male or female patients 18 years or older
Confirmed and measurable metastatic melanoma with at least one measurable lesion for evaluation of response
Meets the requirements for HD IL-2 therapy per Institutional guidelines
Meets the requirements for ipilimumab therapy per Institutional guidelines
Treatment naïve or has received only one systemic therapy apart from adjuvant therapy.
At least 4 weeks since last adjuvant therapy or other cancer treatment
Willing and able to give informed consent and participate in study procedures as described in the 12PLK02 and 10PLK13 protocols. Patients consented for 12PLK02 will also be asked to participate in the 10PLK13 PROCLAIM registry study.

Exclusion Criteria:

Patients with known or suspected infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) or other infectious hepatitis
Pregnant, nursing or planning to become pregnant
Untreated brain metastases. (Brain metastases that have been treated, which no longer require corticosteroid therapy and are without progression by MRI at least 6 weeks after definitive therapy are acceptable.)
Received prior ipilimumab therapy (Prior Adjuvant Ipilimumab and Adjuvant Interferon are permitted with a minimum 4 week washout)
Received prior HD IL-2 therapy.
Received investigational drug within 30 days prior to study dosing. Patients may participate in non-interventional or observational clinical studies, including the 10PLK13 PROCLAIM registry study.
Concomitant disease or condition that would interfere with the conduct of the study or that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this study.

Study is for people with:

Melanoma

Phase:

Phase 4

Estimated Enrollment:

29

Study ID:

NCT01856023

Recruitment Status:

Terminated

Sponsor:

Clinigen, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 12 Locations for this study

See Locations Near You

The University of Arizona Cancer Center
Tucson Arizona, 85724, United States
Moores UCSD Cancer Center
La Jolla California, 92093, United States
MSMC Research Program
Miami Beach Florida, 33140, United States
Oncology Specialists, SC
Park Ridge Illinois, 60068, United States
University of Iowa Hospitals & Clinics
Iowa City Iowa, 52242, United States
Johns Hopkins Medicine
Lutherville Maryland, 21093, United States
Karmanos Cancer Institute
Detroit Michigan, 48201, United States
Nebraska Cancer Specialists, Midwest Cancer Center - Legacy
Omaha Nebraska, 68130, United States
Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center
New York New York, 10032, United States
Duke University Health System
Durham North Carolina, 27710, United States
The Christ Hospital
Cincinnati Ohio, 45219, United States
MD Anderson Cancer Center
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 4

Estimated Enrollment:

29

Study ID:

NCT01856023

Recruitment Status:

Terminated

Sponsor:


Clinigen, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.